title: Understanding IMPROVE-IT and the cardinal role of LDL-C lowering in CVD prevention.
authors.affiliation: Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Geb. 40, Universitätsklinikum des Saarlandes, Homburg/Saar D-66421, Germany ulrich.laufs@uks.eu.
authors.forename: Ulrich
authors.initials: U
authors.lastname: Laufs
authors.affiliation: Lipid Clinic, Hopital de Jolimont, Haine-Saint-Paul, Belgium.
authors.forename: Olivier S
authors.initials: OS
authors.lastname: Descamps
authors.affiliation: Department of Pharmacological and Biomolecular Sciences, University of Milano and Multimedica IRCCS, Milano, Italy.
authors.forename: Alberico L
authors.initials: AL
authors.lastname: Catapano
authors.affiliation: Glasgow Clinical Research Facility, Tennent Building, 38 Church Street, Western Infirmary, Glasgow G11 6NT, UK.
authors.forename: Chris J
authors.initials: CJ
authors.lastname: Packard
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D000924:Anticholesteremic Agents / Q000008:administration & dosage*; D001384:Azetidines / Q000627:therapeutic use*; D006801:Humans; D019821:Simvastatin / Q000008:administration & dosage*
chemical_list: D000924:Anticholesteremic Agents; D001384:Azetidines; D019821:Simvastatin